MIRM
Mirum Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Mirum Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
1.16%
MIRM weight · XBI
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
No other changes.
No other changes.
Last report5 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
Load failed · retrying
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
13F holdings, not covered
Load failed · retrying
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Mirum Pharmaceuticals, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Mirum Pharmaceuticals, Inc.'s 6 closest co-movers, none share that code.
Mirum Pharmaceuticals, Inc.
94.54
+7.51 · +8.63%
Linked news
News| Manager | Value | % base | |
|---|---|---|---|
| Frazier Life Sciences | $899.1M | 10.73% | 0.00% |
| Jupiter Topco | $691.7M | 8.25% | — |
| BlackRockindex-like | $513.9M | 6.13% | +14.13% |
| FMR | $429.7M | 5.13% | +86.75% |
| T. Rowe Price | $310.9M | 3.71% | +54.63% |
| Manager | Value | % base | |
|---|---|---|---|
| Frazier Life Sciences | $899.1M | 10.73% | 0.00% |
| Jupiter Topco | $691.7M | 8.25% | — |
| BlackRockindex-like | $513.9M | 6.13% | +14.13% |
| FMR | $429.7M | 5.13% | +86.75% |
| T. Rowe Price | $310.9M | 3.71% | +54.63% |
+22.46%
shares held · 10 largest managers
Expected move
Inputsspot 87.03exp Mar 19ATM strike 85ATM straddle 27.30IV 66%